Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Conditions: Head and Neck Squamous Cell Carcinoma; Squamous Cell Carcinoma of Anal Canal; Colorectal Cancer; Squamous Cell Carcinoma of the Lung; EGFR Amplification; Epithelial Ovarian Cancer; Pancreas Cancer; Cutaneous Squamous Cell Carcinoma; Head and Neck Neoplasms; Carcinoma, Squamous Cell; Squamous Cell Carcinoma of Head and Neck
Interventions: Drug: BCA101; Drug: Pembrolizumab
Sponsors: Bicara Therapeutics; Merck Sharp & Dohme LLC
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.